Trial Profile
Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Vitamin D-binding protein-macrophage activating factor (Primary) ; Vitamin D-binding protein-macrophage activating factor (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Adverse reactions
- Sponsors Efranat
- 10 Aug 2016 New trial record